Genentech announced the launch of Cotellic (cobimetinib) for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), available immediately at Biologics. Cotellic was approved by the Food and Drug Administration (FDA) on November 10, 2015.

RELATED: FDA Approves New Melanoma Treatment

Physicians may submit Cotellic prescriptions to Biologics via phone [(800) 850-4306, option 2], fax [(800) 823-4506] or eScribe.

Cotellic is available as 20mg dosage strength and is supplied in bottles of 63 tablets.

For more information visit or